Press Releases

 
Press Releases
Date Title and Summary View
Mar 8, 2016 SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  today announced that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the Barclays Capital 2016 Global Healthcare Conference at 2:35 p.m. EDT on March 15, 201...
Mar 8, 2016 SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it...
Feb 23, 2016 SALT LAKE CITY, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced an ...
Feb 22, 2016 SALT LAKE CITY, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a s...
Feb 2, 2016 Total Revenues of $193.3 Million Adjusted Diluted EPS of $0.45 and Diluted EPS of $0.41 Company Maintains Fiscal Year 2016 Revenue Guidance, Raises Fiscal Year 2016 Earnings Guidance and Provides Fiscal Third-Quarter 2016 Financial Guidance ...
Jan 21, 2016 SALT LAKE CITY, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, Feb. 2.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, chief financial ...
Jan 7, 2016 SALT LAKE CITY, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced tha...
Jan 4, 2016 SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 34th annual J.P. Morgan Healthcare Conference at 9:30 a.m. PST (12:30 pm EST) on January 11, 2016, at the Westin St. Francis in S...
Dec 10, 2015 SALT LAKE CITY, Dec. 10, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data will be presented demonstrating the role of the myChoice HRD companion diagnostic in identifying patients with breast cancer who are likely to respond to a platinum-contain...
Dec 9, 2015 SALT LAKE CITY, Dec. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will highlight three scientific presentations related to its myRisk Hereditary Cancer test at the 2015 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. Data include r...
Page: FirstPrevious ...
9
... NextLast
= add release to Briefcase